Details of the Drug

General Information of Drug (ID: DMOWTRL)

Drug Name
GSK-2315698
Synonyms GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline
Indication
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
PubChem CID
125516
TTD ID
D0AY1I
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serum amyloid P-component (APCS) TTB7VAT SAMP_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Amyloidosis
ICD Disease Classification 5D00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serum amyloid P-component (APCS) DTT APCS 3.02E-01 -0.06 -0.21
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
2 Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.